

Food and Drug Administration Silver Spring MD 20993

NDA 22567/S-012

## SUPPLEMENT APPROVAL POSTMARKETING COMMITMENT FULFILLED

Forest Laboratories, Inc. Attention: Michael Olchaskey, Pharm D. Executive Director, Regulatory Affairs Harborside Financial Center, Plaza V Jersey City, NJ 07311

Dear Dr. Olchaskey:

Please refer to your Supplemental New Drug Application (sNDA) dated and received on May 16, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Viibryd (vilazodone hydrochloride) 10 mg, 20 mg, and 40 mg tablets.

We acknowledge receipt of your amendments dated July 14, 2014, July 23, 2014, September 18, 2014, October 9, 2014, October 30, 2014, December 2, 2014, January 16, 2015, February 18, 2015, March 4, 2015, March 9, 2015, and March 11, 2015.

We also refer you to our January 21, 2011 Approval letter in which you agreed to explore lower dose response for effectiveness as a postmarketing commitment (PMC# 1723-8).

This "Prior Approval" supplemental new drug application provides revisions to include a new dosing regimen under the dosing and administration section of the Viibryd label.

## APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

## **CONTENT OF LABELING**

DOCKE

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <a href="http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm">http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm</a>. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

DOCKE<sup>-</sup>

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at <u>http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/U CM072392.pdf</u>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **CARTON AND IMMEDIATE CONTAINER LABELS**

We acknowledge your March 9, 2015, submission containing final printed carton and container labels.

#### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric studies requirement for ages 0 to 6 years for the treatment of Major Depressive Disorder (MDD) because necessary studies are impossible or highly impracticable due to the low prevalence of this disease in these age ranges.

We are deferring submission of your pediatric studies for ages 7 to 17 years for the treatment of MDD because this product is ready for approval use in adults and the pediatric studies have not been completed.

Your deferred pediatric studies required by section 505B(a) of the Federal Food, Drug, and Cosmetic Act are required postmarketing studies. The status of these postmarketing studies must be reported annually according to 21 CFR 314.81 and section 505B(a)(3)(B) of the Federal Food, Drug, and Cosmetic Act. These required studies were communicated in our approval letter dated January 21, 2011.

Submit final reports to this NDA. For administrative purposes, all submissions related to this required pediatric postmarketing study must be clearly designated "Required Pediatric Assessment(s)".

### FULFILLMENT OF POSTMARKETING COMMITMENT

Your May 16, 2014 submission contains the final report for the following postmarketing commitment listed in the January 21, 2011 approval letter.

1723-8 It is not apparent from the trials you have conducted in major depressive disorder that the lowest effective dose of vilazodone has been identified, because only one dose (40 mg/day) was studied. However, there are suggestions that 20 mg/day may be effective at least in some subjects. In one of the trials, those who did not tolerate 40 mg/day could continue in the trial on a dose of 20 mg/day, and some may have had a significant treatment effect. In addition, data from the phase 2 fixed-dose trials suggest that there may have been a signal of efficacy with the 20 mg/day dose, as measured by the secondary efficacy measure (MADRS). Moreover, some important adverse reactions are dose-related. Thus, we request that you further characterize the efficacy and safety of vilazodone in the treatment of adults with MDD using fixed doses of vilazodone (20 mg and 40 mg), an active control (for assay sensitivity), and placebo in an adequate and well controlled trial.

We have reviewed your submission and conclude that the above commitment was fulfilled.

We remind you that there are postmarketing requirements and postmarketing commitments listed in the January 21, 2011 approval letter that are still open.

## PROMOTIONAL MATERIALS

DOCKET

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration Center for Drug Evaluation and Research Office of Prescription Drug Promotion (OPDP) 5901-B Ammendale Road Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at

http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

#### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call CAPT William Bender, Senior Regulatory Project Manager, at (301) 796-2145 or via email at <u>william.bender@fda.hhs.gov</u>.

Sincerely,

*{See appended electronic signature page}* 

Mitchell V. Mathis, M.D. CAPT, USPHS Director Division of Psychiatry Products Office of Drug Evaluation I Center for Drug Evaluation and Research

ENCLOSURES: Content of Labeling Carton and Container Labeling

# This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

-----

/s/

\_\_\_\_\_

MITCHELL V Mathis 03/16/2015